Clinical Guideline

Aciclovir 25mg/mL injection, 200mg tablet, 3% eye ointment

Policy developed by: SA Maternal, Neonatal and Gynaecology Community of Practice
Approved SA Health Safety & Quality Strategic Governance Committee on: 07 March 2017
Next review due: 31 March 2020

Summary
The Aciclovir 25mg/mL injection, 200mg tablet, 3% eye ointment clinical practice guideline for the administration of aciclovir to a neonate

Keywords
aciclovir, acyclovir, acycloguanosine, chickenpox, varicella zoster immune globulin, corticosteroids, herpes simplex, postnatal, renal, intravenous, ophthalmologists, glucose, sodium chloride, vomiting, diarrhoea, encephalopathy, neutropenia, agitation, oedema, constipation, rash, coma, seizures, leucopenia, crystalluria, hepatitis, stevens-johnson syndrome, necrolysis, anaphylactic shock, liver function, visual turbidity, crystallisation, clinical guideline, Aciclovir 25mg/mL injection, 200mg tablet, 3% eye ointment

Policy history
Is this a new policy? N
Does this policy amend or update an existing policy? Y v3.0
Does this policy replace an existing policy? N

Applies to
All Health Networks
CALHN, SALHN, NALHN, CHSALHN, WCHN

Staff impact
All Staff

PDS reference
CG004

Version control and change history

<table>
<thead>
<tr>
<th>Version</th>
<th>Date from</th>
<th>Date to</th>
<th>Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>November 2012</td>
<td>06 March 2017</td>
<td>Original Version</td>
</tr>
<tr>
<td>2.0</td>
<td>07 March 2017</td>
<td>Current</td>
<td>Review and update</td>
</tr>
</tbody>
</table>

© Department for Health and Ageing, Government of South Australia. All rights reserved.


Note

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

• The use of interpreter services where necessary,
• Advising consumers of their choice and ensuring informed consent is obtained,
• Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
• Documenting all care in accordance with mandatory and local requirements

Synonyms

acyclovir, acycloguanosin
**Dose and Indications**

- Neonates presenting with chickenpox who are unwell (e.g., poor feeding, tachypnoea), whether or not they received Varicella Zoster Immune Globulin (VZIG).
- Any immunocompromised neonate who develops chickenpox, including those who are premature or being treated with corticosteroids, whether or not they received VZIG.
- Any otherwise high risk neonate (judged by the clinician) who develops chickenpox and in whom VZIG prophylaxis was not given within 24 hours of exposure.
- Herpes simplex treatment or prophylaxis.

**Intravenous**

<table>
<thead>
<tr>
<th>Corrected Age</th>
<th>Dose (mg/kg/dose)</th>
<th>Frequency (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational Age PLUS Postnatal Age (weeks)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 30 weeks</td>
<td>20mg/kg/dose</td>
<td>every 12 hours</td>
</tr>
<tr>
<td>≥30 weeks</td>
<td>20mg/kg/dose</td>
<td>every 8 hours</td>
</tr>
</tbody>
</table>

The dosing interval must be at least doubled if there is renal failure.

Length of therapy should be guided by clinical picture, underlying pathology and specialist consultation; however, usually for a minimum of 14 days for a confirmed infection.

**Ocular**

Apply five times a day.

Treat for 14 days or for at least 3 days after healing is complete, whichever is shorter.

Use with intravenous therapy under ophthalmologist’s supervision.

**Oral**

Suppressive therapy, for infants with HSV encephalitis.

20mg/kg/dose, three times a day for 6 months after completion of IV treatment.
Preparation and Administration

**Intravenous**

Dilute 2mL of the 25mg/mL aciclovir injection with 8mL sodium chloride 0.9% (to a total volume of 10mL). Shake well to ensure thorough mixing. The resulting solution contains 5mg/mL aciclovir.

<table>
<thead>
<tr>
<th>Dose</th>
<th>10mg</th>
<th>20mg</th>
<th>30mg</th>
<th>40mg</th>
<th>50mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>2mL</td>
<td>4mL</td>
<td>6mL</td>
<td>8mL</td>
<td>10mL</td>
</tr>
</tbody>
</table>

Infuse over 1 hour.

Discard remaining solution.

**Ocular**

Clean the eye of all secretions. Place the neonate on their back. Do not touch the patient with the tip of the tube. Pull lower lid down and squeeze out a line of ointment. By rotating the tube when you reach the outer eye, you will help detach the ointment from the tube.

**Oral**

The lowest strength tablet available is 200mg. It is recommended to round off the dose to the nearest quarter of a tablet and give dispersed in small amount of water (5-10mL)

**Compatible Fluids**

Glucose 5%, Glucose Sodium Chloride combinations, Sodium chloride 0.9%

**Adverse Effects**

**Common**

Vomiting, diarrhoea, encephalopathy, injection site reactions, neutropenia

**Infrequent**

Agitation, oedema, renal impairment, constipation, rash

**Rare**

Coma, seizures, leucopenia, crystalluria, hepatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis.

Anaphylactic shock is not commonly seen in the neonates

**Monitoring**

- Periodic full blood count
- Periodic renal and liver function
Practice Points

> Oral acyclovir has poor oral bioavailability. Intravenous administration is the preferred route in neonates
> Slow infusion and adequate hydration can minimise renal toxicity caused by precipitation of aciclovir in renal tubules.
> Discard the solution if visual turbidity or crystallisation occurs before or during infusion.
> Store at room temperature, to prevent precipitation.
> Maternal chickenpox in the peripartum period poses a risk of severe neonatal varicella, with a mortality rate up to 30%. The timing of maternal infection in relation to delivery determines the risk to the infant.
> If required, Varicella Zoster Immunoglobulin (VZIG) should be given to the baby as early as possible after delivery or exposure, but must be within 72 hours.

Reference